Skip to main content

Table 4 Major molecular response at 12 months

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Intervention Mean 95%LCrI 95%UCrI
Probability of response
Imatinib 400 mg daily 33.6% Reference category
Dasatinib 100 mg daily 51.1% 43.9% 58.5%
Nilotinib 300 mg twice daily 58.7% 49.6% 67.5%
Nilotinib 400 mg twice daily 57.8% 48.7% 66.8%
Imatinib 800 mg daily 48.1% 43.1% 53.1%
Response Odds Ratios
Imatinib 400 mg daily N/A Reference category
Dasatinib 100 mg daily 2.09 1.55 2.78
Nilotinib 300 mg twice daily 2.87 1.95 4.11
Nilotinib 400 mg twice daily 2.76 1.88 3.98
Imatinib 800 mg daily 1.84 1.50 2.24
  1. LCrI: Lower boundary of derived credible interval; UCrI: Upper foundry of derived credible interval.